Economic Considerations in a Changing Anemia Environment

American Journal of Kidney Diseases

Volumn 52, Issue 6 SUPPL. 1, 2008, Pages

  Pizzi, Laura T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

anemia of chronic kidney disease; anemia treatment costs; hemodialysis; Intravenous iron; Medicare reimbursement

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN;

ANEMIA; CHRONIC KIDNEY DISEASE; COST CONTROL; COST OF ILLNESS; DIALYSIS; DRUG EFFICACY; HUMAN; MEDICARE; MONEY; PROSPECTIVE PAYMENT; REIMBURSEMENT; REVIEW;

ANEMIA; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRITINS; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MEDICAID; MEDICARE; RENAL DIALYSIS; TRANSFERRIN; UNITED STATES;

EID: 55749088196     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.09.001     Document Type: Review

References (16)

1. Thamer M., Zhang Y., Kaufman J., Cotter D., Dong F., and Hernán M.A. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
2. Wish J.B. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl 70 (2006) S21-S25
3. Leavitt M.O. Secretary of Health and Human Services Report to Congress: A Design for a Bundled End-Stage Renal Disease Prospective Payment System, 2008. http://www.cms.hhs.gov/ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdf Accessed April 24, 2008
4. US Renal Data System. USRDS 2007 Annual Data Report (2007), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
5. FDA. Aranesp (darbepoetin alfa) for injection: Prescribing information (March 2008), US Food and Drug Administration (USFDA), Silver Spring, MD
6. FDA. Procrit (epoetin alfa) for injection: Prescribing information (March 2008), US Food and Drug Administration (USFDA), Silver Spring, MD
7. Sunder-Plassmann G., and Hörl W.H. Erythropoietin and iron. Clin Nephrol 47 (1997) 141-157
8. Taylor J.E., Peat N., Porter C., and Morgan A.G. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11 (1996) 1079-1083
9. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46
10. Sepandj F., Jindal K., West M., and Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11 (1996) 319-322
11. Michael B., Trout J.R., Hoel G., et al. Effectiveness of continuous low-dose intravenous ferric gluconate therapy for maintaining Hgb and decreasing epoetin requirements in hemodialysis patients. Presented at: American Society of Nephrology Annual Meeting, San Francisco, CA, November 2 (2007) (abstr)
12. Sunder-Plassmann G., and Hörl W.H. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10 (1995) 2070-2076
13. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
14. Coyne D.W., Kapoian T., Suki W., et al., DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
15. Pizzi L.T., Bunz T.J., Goldfarb D.S., Coyne D.W., Singh A.K., et al. Ferric gluconate yields cost-savings in hemodialysis patients with high ferritin and low TSAT: Results from the DRIVE studies. Presented at: American Society of Nephrology Annual Meeting, San Francisco, CA, November 2 (2007) (abstr)
16. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S11-S145